Chemistry:Clevudine
From HandWiki
Short description: Chemical compound
![]() | |
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII |
|
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C10H13FN2O5 |
Molar mass | 260.221 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Clevudine (INN) is an antiviral drug for the treatment of hepatitis B (HBV). It is already approved for HBV in South Korea and the Philippines . It is marketed by Bukwang Pharmaceuticals in South Korea under the tradenames Levovir and Revovir.
Researchers in South Korea are testing clevudine at lower doses in combination with adefovir for continued use.[2]
It is a nucleoside analog.[3]
References
- ↑ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcddd/new_atc_ddd.html#ATCDDD_FINAL.
- ↑ "A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients.". Hepatology International 8 (3): 375–381. May 2014. doi:10.1007/s12072-014-9537-5. PMID 25101150.
- ↑ "A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B". Hepatology 43 (5): 982–8. May 2006. doi:10.1002/hep.21166. PMID 16628625.
![]() | Original source: https://en.wikipedia.org/wiki/Clevudine.
Read more |